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2001). This ran counter to earlier findings based on a HDAC4: A Corepressor Controlling
less sensitive marker (Grounds, 1983) and is flatly con- Bone Developmenttradicted by the Sherwood study, but the sporadic entry
of cells derived from whole bone marrow grafts into the
myogenic process, seemingly by a number of pathways,
is vindicated, and sustains some hope of therapeutic RUNX2 is a transcription factor with a well-character-
applicability. This study also failed to confirm the thesis ized role in bone development. In this issue of Cell,
that CD45 cells residing in muscle act as a significant Vega and colleagues (Vega et al., 2004) show that
source of myogenic stem cells, (Polesskaya et al., 2003) HDAC4 interacts with RUNX2 and impacts upon chon-
but the original claim was made on the basis of a four drocyte hypertrophy and bone formation.
day postinjury model rather than the two day setup used
here, and one should be wary of the transience of ex- Histone deacetylases (HDACs) are transcriptional coreg-
pression of some of the markers used in the majority of ulators with the capability of modifying chromatin struc-
these studies. Doubt as to the applicability of general ture and other transcription factors. HDACs fall into two
principles between species must also be born in mind, general classes based on sequence homology and do-
especially in view of the recent description of what ap- main structure. Class I HDACs have homology to yeast
pears to be a robust myogenic activity in vivo among a RPD3 and lack an N-terminal domain present in class
tiny minority population of circulating cells in human II proteins. Class II HDACs are homologous to yeast
blood (Torrente et al., 2004). HDA1 and have an N-terminal extension that regulates
Undoubtedly, the main impact of the Sherwood paper activity. HDACs are emerging in vital cellular processes
is to consolidate the view that the contribution of cells including growth, differentiation, and apoptosis, among
derived from the bone marrow into regenerating skeletal others. They are of interest as pharmacological targets
muscle under normal physiological circumstances is in cancer and in cardiac pathology. Because of their
trivial. Although it does not completely invalidate the widespread importance and enormous clinical potential,
notion of therapeutic application of this mechanism, it a clear understanding of their functions in vivo is urgent.
certainly provides no encouragement. However, the fact The Olson laboratory has made dedicated efforts to
that some bone marrow cells can be persuaded into the characterizing the class II HDACs. Recently, they dem-
myogenic pathway remains as a tantalizing conundrum. onstrated a critical role in modulating the growth re-
What is the nature of this phenomenon? In itself, it is too sponse of cardiac muscle to work (Chang et al., 2004;
ineffectual to be selectable by Darwinian mechanisms. Zhang et al., 2002). Loss-of-function in HDAC5 or
Could it be an ancillary of some more biologically impor- HDAC9 results in cardiac hypertrophy in unchallenged
tant process or is it simple biological “noise” within the mice, and the deficiencies cause hypersensitivity to car-
mechanisms of differentiation? diac stress such as banding of the thoracic aorta or
ectopic expression of calcineurin. Conversely, a gain-
of-function mutation in a product of the HDAC9 gene
Terence Partridge inhibits cardiomyocyte hypertrophy in vitro. The pheno-
Muscle Cell Biology Group typic effects of the class II HDACs are, at least in part,
MRC Clinical Sciences Centre associated with MEF2, a transcription factor connected
Du Cane Road with cardiac hypertrophy. Thus, two class II HDACs have
London, W12 0NN in vivo roles in a pathway controlling cardiac cell growth,
United Kingdom and their activity is mediated by a key DNA binding
transcription factor.
In this issue of Cell, the Olson laboratory proposesSelected Reading
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RUNX2 function slows bone development, and gain-of-
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HDAC4 and RUNX2. Vega and colleagues propose a
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Biol. Chem. 279, 41998–42007.precipitations. These striking observations suggest that
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A.J., Stein, J.L., Schwarz, E.M., O’Keefe, R.J., Stein, G.S., and Drissi,ability to interfere with RUNX2.
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to bone development. Future analyses will likely provide
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have roles in bone development and share homology Westendorf, J.J., Zaidi, S.K., Cascino, J.E., Kahler, R., van Wijnen,
with RUNX2, making them prime candidates for interac- A.J., Lian, J.B., Yoshida, M., Stein, G.S., and Li, X. (2002). Mol. Cell.
tion with HDAC4 (Smith et al., 2004; Yoshida et al., 2004). Biol. 22, 7982–7992.
More detailed studies of mutants defective for the Yoshida, C.A., Yamamoto, H., Fujita, T., Furuichi, T., Ito, K., Inoue,
HDAC4-RUNX2 interaction will likely help to refine the K., Yamana, K., Zanma, A., Takada, K., Ito, Y., and Komori, T. (2004).
Genes Dev. 18, 952–963.mechanism by which HDAC4 influences chondrocyte
Zhang, C.L., McKinsey, T.A., Chang, S., Antos, C.L., Hill, J.A., andgrowth.
Olson, E.N. (2002). Cell 110, 479–488.The data presented by Vega and colleagues reinforce
the importance of HDACs to bone development in vivo
(Vega et al., 2004). To date, three HDACs (3, 4, and 6)
have been shown to contribute to RUNX2 activity in vitro.
HDAC3 is a class I enzyme that binds the N terminus of
Silence of the RingsRUNX2 and is important for RUNX2 repression in several
cell lines (Schroeder et al., 2004). HDAC6 is a class II
enzyme that binds the C terminus of RUNX2 and is better
known for its tubulin deacetylase activity (Westendorf
Two recent papers (de Napoles et al., 2004 and Wang
et al., 2002). Lessons from the cardiomyocyte model
et al., 2004) have linked monoubiquitylation of histone
suggest that multiple HDACs participate in the same
H2A to the activities of E3 ubiquitin ligases that residepathway while contributing unique, nonredundant func-
in Polycomb-group repressor complexes.tions. Recall that a deficiency of either HDAC5 or HDAC9
is sufficient to produce cardiac hypertrophy, indicating
The awarding of the 2004 Nobel prize in Chemistry tothat the two genes have some activities that are not
Aaron Ciechanover, Avram Hershko, and Irwin Roseshared (Chang et al., 2004). Bone development might
recognized their seminal contributions to the field ofbe similar in that multiple HDACs are required for appro-
ubiquitin-mediated protein turnover. Yet, it is worth re-priate regulation of downstream transcription factors.
membering that the first ubiquitylated protein identifiedAlternatively, other HDACs could contribute to different
in eukaryotes was a chromatin protein—histone H2A—temporal or spatial aspects of bone development. For
that does not undergo proteolysis (Goldknopf et al.,example, there could be an HDAC requirement for
1975). In contrast to proteins targeted for degradation,RUNX2-dependent intramembranous bone develop-
which contain long chains of ubiquitin, H2A and otherment or for later stages of endochondral development.
histones that carry this modification are monoubiquity-The HDAC4 phenotype inspires many new hypotheses.
lated. The significance of this form of ubiquitin attach-The discovery that HDAC4 impacts upon chondrocyte
ment remained a puzzle for more than two decades,hypertrophy provides exciting new information about
until it was shown that monoubiquitylation played a keyan important transcription factor. The observation that
role in endocytosis and intracellular protein trafficking.HDACs 4, 5, and 9 are linked to hypertrophic growth
In these systems, ubiquitin was found to provide a pro-raises additional questions about general properties of
tein interaction surface, thus ensuring targeting ofthis class of transcription factors. As the phenotypes of
monoubiquitylated proteins to the proper cellular com-other HDAC mutations are probed in detail, it will be
partment (Hicke, 2001). The notion that monoubiquityla-exciting to learn whether this class of proteins has a
general role controlling cell growth. tion of histones might provide an analogous role in chro-
